The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R.sub.2 is H, halogen, C.sub.1-12 alkyl or C.sub.1-12 haloalkyl; and R.sub.3 is C.sub.3-6 cycloalkyl, C.sub.1-12 alkyl, C.sub.1-12 haloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4-alkylene, aryl-C.sub.1-4-alkylene or heteroaryl-C.sub.1-4-alkylene, wherein said aryl-C.sub.1-4-alkylene and heteroaryl-C.sub.1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of .alpha.-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.